Education
About Us
Working with TipRanks
Follow Us
Esperion (ESPR)
NASDAQ:ESPR
ESPR Stock Chart & Stats
$2.90
-$0.02(-0.92%)
At close: 4:00 PM EST
$2.90
-$0.02(-0.92%)
Day’s Range― - ―
52-Week Range$0.69 - $3.94
Previous CloseN/A
Volume1.55M
Average Volume (3M)7.09M
Market Cap
$693.28M
Enterprise Value$1.04B
Total Cash (Recent Filing)$92.45M
Total Debt (Recent Filing)$600.99M
Price to Earnings (P/E)―
Beta2.55
Next Earnings
Feb 24, 2026EPS Estimate
0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding239,063,430
10 Day Avg. Volume7,079,476
30 Day Avg. Volume7,086,976
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-1.06
Price to Sales (P/S)1.24
P/FCF Ratio-17.18
Enterprise Value/Market Cap1.50
Enterprise Value/Revenue3.41
Enterprise Value/Gross Profit6.38
Enterprise Value/Ebitda-37.95
Forecast
1Y Price Target
$6.94Price Target Upside139.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe entry into the Japanese market, one of the top three global markets for cardiovascular prevention, represents a major step forward for Esperion.
Regulatory ApprovalsRegulatory approval for NEXLETOL in Japan marks a significant milestone, expanding Esperion's commercial reach.
Revenue GrowthEsperion is poised to receive milestone payments and additional royalties from Otsuka based on net sales achievements in Japan.
Bears Say
Competitive ChallengesThe rapidly expanding competitive landscape suggests bempedoic acid may have more of a niche role.
Financial PerformanceEsperion announced 3Q25 financial results, posting EPS of ($0.16), compared to our estimate of ($0.11), and consensus of ($0.08).
Product StrategyPrescriber feedback was mixed on Esperion’s triple fixed-dose combination strategy.
Esperion News
ESPR FAQ
What was Esperion’s price range in the past 12 months?
Esperion lowest stock price was $0.69 and its highest was $3.94 in the past 12 months.
What is Esperion’s market cap?
Esperion’s market cap is $693.28M.
When is Esperion’s upcoming earnings report date?
Esperion’s upcoming earnings report date is Feb 24, 2026 which is in 99 days.
How were Esperion’s earnings last quarter?
Esperion released its earnings results on Nov 06, 2025. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.078 by -$0.082.
Is Esperion overvalued?
According to Wall Street analysts Esperion’s price is currently Undervalued.
Does Esperion pay dividends?
Esperion does not currently pay dividends.
What is Esperion’s EPS estimate?
Esperion’s EPS estimate is 0.28.
How many shares outstanding does Esperion have?
Esperion has 239,063,430 shares outstanding.
What happened to Esperion’s price movement after its last earnings report?
Esperion reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.078. Following the earnings report the stock price went down -14.966%.
Which hedge fund is a major shareholder of Esperion?
Currently, no hedge funds are holding shares in ESPR
Esperion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.94 (139.31% Upside)
$6.94 (139.31% Upside)
Blogger Sentiment
Bullish
ESPR Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 558.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $20.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.89%
Trailing 12-Months
Company Description
Esperion
Esperion Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). The company operates primarily in the pharmaceutical sector, concentrating on cardiovascular diseases. Esperion's core products include bempedoic acid and its combination therapy with ezetimibe, aimed at providing effective solutions for individuals who are unable to achieve their cholesterol goals with traditional statin therapy.
ESPR Company Deck
ESPR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong revenue growth, successful strategic initiatives, and international expansion. However, increased operating expenses and onetime financial impacts were noted as challenges. Overall, the highlights of growth and strategic progress outweigh the lowlights.View all ESPR earnings summariesESPR Stock 12 Month Forecast
Average Price Target
$6.94
▲(139.31% Upside)
Technical Analysis
Ownership Overview
1.32% Insiders
9.21% Mutual Funds
14.39% Other Institutional Investors
66.81% Public Companies and
Individual Investors